[go: up one dir, main page]

MXPA01011905A - Compuestos novedosos, su uso y preparacion. - Google Patents

Compuestos novedosos, su uso y preparacion.

Info

Publication number
MXPA01011905A
MXPA01011905A MXPA01011905A MXPA01011905A MXPA01011905A MX PA01011905 A MXPA01011905 A MX PA01011905A MX PA01011905 A MXPA01011905 A MX PA01011905A MX PA01011905 A MXPA01011905 A MX PA01011905A MX PA01011905 A MXPA01011905 A MX PA01011905A
Authority
MX
Mexico
Prior art keywords
ring
saturated
disorders
substituted
ring members
Prior art date
Application number
MXPA01011905A
Other languages
English (en)
Inventor
Bjoern Nilsson
Original Assignee
Biovitrum Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9901884A external-priority patent/SE9901884D0/xx
Application filed by Biovitrum Ab filed Critical Biovitrum Ab
Publication of MXPA01011905A publication Critical patent/MXPA01011905A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/18—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La invencion se relaciona con compuestos de la formula general (I) en donde Ar opcionalmente es arilo o heteroarilo sustituido; A es (i) -O-, -S-, -SO2-, -NH-, (ii) un alquilo de C1-4 o un atomo de nitrogeno sustituido con acilo de C1-6 o (iii) una cadena de alquileno de C1-8 o una cadena de heteroalquileno que tiene de 2 a 8 atomos en la cadena, que contiene opcionalmente al menos una insaturacion, y que puede estar sustituida y/o contener un puente para formar un anillo saturado, o parcial o completamente insaturado que tenga de 3 a 8 miembros en el anillo; B es - C (R4) (R5) -, - OC (R4) (R5)-, -N (R6) C (R4) (R5) -, -N (R6) -O- , -S- o -SO2-; R es cicloalquilo, arilo o heteroarilo de C3-8 sustituido opcionalmente; R1 es (i) un anillo azaciclico o amino azaciclico saturado o insaturado, o un anillo diazaciclico o amino diazaciclico saturado, que tiene de 4 a 7 miembros en el anillo o un anillo saturado aminoazabiciclico, azabiciclico o diazabiciclico que tiene de 7 a 10 miembros en el anillo, estos anillos se sustituyen opcionalmente en una o mas posiciones, o un grupo - [C(R4) (R5)] xN(R2a) (R3a)]; R2a, R3a, R4, R5, R6 y x son como se definieron en las reivindicaciones y n es 0 1; y las sales, hidratos y formas de profarmaco farmaceuticamente aceptables de los mismos. Los compuestos se pueden preparar per se mediante metodos convencionales y se pueden utilizar para tratar a un sujeto humano o animal que sufre de un trastorno relacionado con la serotonina, tales como trastornos de alimentacion, en especial obesidad, trastornos de la memoria, esquizofrenia, trastornos del estado de animo, trastornos de ansiedad, dolor, disfunciones sexuales y trastornos urinarios. La invencion tambien se relaciona con este uso, asi como tambien con las composiciones farmaceuticas que comprenden un compuesto de la formula (I).
MXPA01011905A 1999-05-21 2000-05-19 Compuestos novedosos, su uso y preparacion. MXPA01011905A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9901884A SE9901884D0 (sv) 1999-05-21 1999-05-21 Novel compounds their use and preparation
US13752799P 1999-06-03 1999-06-03
PCT/SE2000/001017 WO2000076984A2 (en) 1999-05-21 2000-05-19 Novel compounds, their use and preparation

Publications (1)

Publication Number Publication Date
MXPA01011905A true MXPA01011905A (es) 2004-03-19

Family

ID=26663577

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA01011905A MXPA01011905A (es) 1999-05-21 2000-05-19 Compuestos novedosos, su uso y preparacion.

Country Status (17)

Country Link
EP (1) EP1178973B1 (es)
KR (1) KR100722090B1 (es)
CN (1) CN1242995C (es)
AT (1) ATE313535T1 (es)
AU (1) AU777276C (es)
BR (1) BR0010783A (es)
CA (1) CA2374898C (es)
DE (1) DE60024986T2 (es)
DK (1) DK1178973T3 (es)
EA (1) EA005820B1 (es)
ES (1) ES2252004T3 (es)
HK (1) HK1048311B (es)
IL (2) IL146582A0 (es)
MX (1) MXPA01011905A (es)
NO (1) NO322220B1 (es)
NZ (1) NZ515786A (es)
WO (1) WO2000076984A2 (es)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0004245D0 (sv) 2000-11-20 2000-11-20 Pharmacia Ab Novel compounds and their use
SE0004244D0 (sv) 2000-11-20 2000-11-20 Pharmacia Ab Novel compounds and their use
ATE433962T1 (de) 2000-11-20 2009-07-15 Biovitrum Ab Publ Piperazinylpyrazinverbindungen als antagonisten des serotonin-5-ht2-rezeptors
GB0109103D0 (en) * 2001-04-11 2001-05-30 Pfizer Ltd Novel compounds
US20030207857A1 (en) 2001-04-11 2003-11-06 Adam Mavis D. Phenyl heterocyclyl ethers
US6825198B2 (en) 2001-06-21 2004-11-30 Pfizer Inc 5-HT receptor ligands and uses thereof
JP2005519876A (ja) * 2001-11-27 2005-07-07 メルク　エンド　カムパニー　インコーポレーテッド ２−アミノキノリン化合物
CN100343240C (zh) * 2002-03-29 2007-10-17 先灵公司 手性2－甲基－4－保护的哌嗪的立体选择性烷基化
US6989392B2 (en) 2002-06-18 2006-01-24 Abbott Laboratories 2-Aminoquinolines as melanin concentrating hormone receptor antagonists
WO2003105850A1 (en) * 2002-06-18 2003-12-24 Abbott Laboratories 2-aminoquinolines as melanin concentrating hormone receptor antagonists
CA2723494C (en) 2002-06-19 2013-04-16 Biovitrum Ab (Publ) 2-methyl piperazine derivatives for treatment of serotonin-related disorders
US7226925B2 (en) 2002-06-19 2007-06-05 Biovitrum Ab Compounds, their use and preparation
JP4592417B2 (ja) * 2002-06-19 2010-12-01 プロキシマゲン・リミテッド 新規方法
AU2003243089B2 (en) * 2002-06-19 2010-01-07 Biovitrum Ab (Publ) Novel compounds, their use and preparation
SE0202287D0 (sv) * 2002-07-19 2002-07-19 Biovitrum Ab New compounds
EP1534391B1 (en) 2002-07-19 2007-02-14 Biovitrum AB Novel piperazinyl-pyrazinone derivatives for the treatment of 5-ht2a receptor-related disorders
US8013156B2 (en) 2003-03-19 2011-09-06 Exelixis, Inc. Tie-2 modulators and methods of use
CL2004000826A1 (es) * 2003-04-25 2005-03-04 Pfizer Uso de un agonista para el receptor 5-ht2c para preparar un medicamento util en el tratamiento de la incontinencia urinaria provocada por estres, con la condicion de que el agonista no sea 1-[6-cloro-5-(trifluorometil)-2-piridinil]piperazina (org-129
WO2005037199A2 (en) 2003-10-10 2005-04-28 Bristol-Myers Squibb Company Pyrazole derivatives as cannabinoid receptor modulators
WO2005097751A2 (en) * 2004-03-31 2005-10-20 Janssen Pharmaceutica, N.V. Non-imidazole heterocyclic compounds as histamine h3-receptor ligands
WO2006022420A1 (ja) * 2004-08-25 2006-03-02 Takeda Pharmaceutical Company Limited 腹圧性尿失禁の予防・治療剤及びそのスクリーニング方法
GT200500317A (es) 2004-11-05 2006-10-27 Proceso para preparar compuestos de quinolina y productos obtenidos de los mismos
AU2005308523B2 (en) 2004-11-29 2010-01-07 Warner-Lambert Company Llc Therapeutic pyrazolo[3,4-b] pyridines and indazoles
NZ560917A (en) 2005-03-31 2011-01-28 Pfizer Prod Inc Cyclopentapyridine and tetrahydroquinoline derivatives
AR054849A1 (es) 2005-07-26 2007-07-18 Wyeth Corp Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas
KR20080107430A (ko) * 2006-03-24 2008-12-10 와이어쓰 방광 기능 조절 방법
PE20081192A1 (es) * 2006-03-24 2008-10-07 Wyeth Corp Tratamiento del dolor
JP5528699B2 (ja) 2006-05-16 2014-06-25 武田薬品工業株式会社 縮合複素環化合物およびその用途
WO2007143422A2 (en) 2006-05-30 2007-12-13 Janssen Pharmaceutica N.V. Substituted pyridyl amide compounds as modulators of the histamine h3 receptor
EP3078662A1 (en) 2007-09-21 2016-10-12 Array Biopharma, Inc. Pyridin-2-yl-amino-1,2,4-thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus
JP5520051B2 (ja) 2007-11-15 2014-06-11 武田薬品工業株式会社 縮合ピリジン誘導体およびその用途
KR101546712B1 (ko) 2007-11-20 2015-08-24 얀센 파마슈티카 엔.브이. 히스타민 ｈ3 수용체의 조절제로서 사이클로알킬옥시- 및 헤테로사이클로알킬옥시피리딘 화합물
AU2010313397B2 (en) * 2009-10-30 2015-07-02 Janssen Pharmaceutica Nv Phenoxy-substituted pyrimidines as opioid receptor modulators
AU2010313401B2 (en) 2009-10-30 2015-07-23 Janssen Pharmaceutica Nv Pyrimidine compounds as delta opioid receptor modulators
CN102791703B (zh) 2009-10-30 2014-07-09 詹森药业有限公司 用作δ阿片类受体调节剂的吡嗪
EP2510949A4 (en) 2009-12-11 2013-11-13 Astellas Pharma Inc THERAPEUTICS FOR FIBROMYALGIA
US20130267500A1 (en) 2010-09-01 2013-10-10 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists in the treatment of disorders ameliorated by reduction of norepinephrine level
EA201390476A1 (ru) 2010-09-28 2013-08-30 Бристол-Майерс Сквибб Компани Новые пиперазиновые аналоги с замещенными гетероарильными группами в качестве противовирусных средств широкого применения против гриппа
JP6216326B2 (ja) 2011-12-22 2017-10-18 カンセラ・アクチエボラグ 炎症および癌の処置において有用なビスアリールスルホンアミド
GB201312129D0 (en) * 2013-07-05 2013-08-21 Proximagen Ltd Drug combination and its use in therapy
GB201312131D0 (en) * 2013-07-05 2013-08-21 Proximagen Ltd Drug combination and its use in therapy
WO2015066344A1 (en) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
CN105348204B (zh) * 2015-11-18 2018-09-14 乳源瑶族自治县大众药品贸易有限公司 1-杂环基-2-(杂芳基硫基)苯衍生物及其使用方法和用途
CN105461635B (zh) * 2015-11-18 2018-06-08 乳源瑶族自治县大众药品贸易有限公司 苯基哌嗪衍生物及其使用方法和用途
CN108409729B (zh) * 2017-02-09 2020-11-24 广东东阳光药业有限公司 苯基八氢-1H-吡啶并[1,2-a]吡嗪衍生物及其用途
EP3733204A4 (en) 2017-12-27 2021-09-15 Takeda Pharmaceutical Company Limited THERAPEUTIC AGENT FOR URINARY INCONTINENCE OF STRESS AND FECAL INCONTINENCE
CN109111383B (zh) * 2018-09-14 2020-11-24 广东东阳光药业有限公司 2-取代的二苯硫醚衍生物及其用途
US20200115389A1 (en) 2018-09-18 2020-04-16 Nikang Therapeutics, Inc. Fused tricyclic ring derivatives as src homology-2 phosphatase inhibitors
CN114394887A (zh) * 2022-01-28 2022-04-26 江苏锐鸣材料科技有限公司 一种苯基氧乙醇化合物及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI193974A7 (es) * 1973-07-13 1975-01-14 Merck & Co Inc
GB9313913D0 (en) * 1993-07-06 1993-08-18 Smithkline Beecham Plc Novel compounds
GB9420999D0 (en) * 1994-10-18 1994-12-07 Smithkline Beecham Plc Novel compounds
AU4037699A (en) * 1998-05-08 1999-11-29 Akzo Nobel N.V. Novel aryl-hydro naphthalenal kanamines

Also Published As

Publication number Publication date
DE60024986T2 (de) 2006-07-27
ES2252004T3 (es) 2006-05-16
WO2000076984A8 (en) 2001-07-19
WO2000076984A3 (en) 2001-02-08
IL146582A0 (en) 2002-07-25
NZ515786A (en) 2004-01-30
WO2000076984A2 (en) 2000-12-21
EA005820B1 (ru) 2005-06-30
AU777276C (en) 2005-07-07
KR20020016795A (ko) 2002-03-06
AU4969000A (en) 2001-01-02
DK1178973T3 (da) 2006-05-08
NO20015686L (no) 2002-01-15
AU777276B2 (en) 2004-10-07
CA2374898A1 (en) 2000-12-21
CN1242995C (zh) 2006-02-22
EP1178973B1 (en) 2005-12-21
HK1048311B (zh) 2006-08-11
KR100722090B1 (ko) 2007-05-25
IL146582A (en) 2010-04-29
EA200101223A1 (ru) 2002-06-27
ATE313535T1 (de) 2006-01-15
NO322220B1 (no) 2006-08-28
DE60024986D1 (de) 2006-01-26
HK1048311A1 (en) 2003-03-28
EP1178973A2 (en) 2002-02-13
NO20015686D0 (no) 2001-11-21
BR0010783A (pt) 2002-04-09
CA2374898C (en) 2009-12-08
CN1360583A (zh) 2002-07-24

Similar Documents

Publication Publication Date Title
IL146582A0 (en) Novel compounds, their use and preparation
PL365163A1 (en) Aryl fused azapolycyclic compounds
MY136270A (en) Processes and intermediates for preparing anti-cancer compounds
UA66825C2 (uk) Азаполіциклічні сполуки, конденсовані з арилом, фармацевтична композиція, спосіб лікування та спосіб зниження нікотинової залежності
GEP20104959B (en) Bicyclic [3.1.0] derivatives as glycine transporter inhibitors
MXPA04001323A (es) Dihidro-3-halo-1h-pirazol-5-carboxilatos sustituidos, su preparacion y uso.
SE0104332D0 (sv) Therapeutic agents
UY25679A1 (es) Derivados de quinolin-2-ona inhibidores de la farnesil proteína transferasa útiles como agentes contra el cáncer
LU91761I2 (fr) Vernakalant et ses dérivés pharmaceutiquement acceptables et en particulier son sel d'hydrochlorure (BRINAVESS®)
YU11501A (sh) Derivati 4,4,-biarilpiperidina sa aktivnošću na receptor opijata
MY126917A (en) Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors
MY133445A (en) 2-arylethyl-(piperidin-4-ylmethyl)amine derivetives
MY133474A (en) Aryl fused azapolycyclic compounds
ATE66913T1 (de) Amidverbindungen, verfahren zu ihrer herstellung und zusammensetzung zur aktivierung gastromotorischer funktionen.
SE9901884D0 (sv) Novel compounds their use and preparation
ATE211137T1 (de) Substituierte benzylthienylpiperazine, ihre anwendung als arzneimittel und verfahren für ihre herstellung
MXPA04005077A (es) Derivados de benzotiazol.
WO2002094768A3 (en) Aza hydroxylated ethyl amine compounds
MXPA06000892A (es) Compuestos azapoliciclicos arilo fusionados.
MXPA04005185A (es) Compuestos hexaciclicos.
EP1057829A4 (en) Condensed pyrimidine derivatives and pharmaceutical compositions containing them
TH52204A (th) อนุพันธ์ (เบนโซไดออกเซน, เบนโซฟิวเรน หรือ เบนโซไพเรน) ที่มีคุณสมบัติฟันดิก รีแลกเซชั่น
MXPA04003688A (es) Compuestos azapoliciclicos condensados con arilo.

Legal Events

Date Code Title Description
FG Grant or registration